Relaxant Effects of Vasoactive Intestinal Peptide and Peptide Histidine Isoleucine in Human and Bovine Pulmonary Arteries
Blood Vessels · 2008
DOI: 10.1159/000158670 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Blood Vessels, 2008. Verfasst von B Greenberg und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
We studied the functional effects of vasoactive intestinal peptide (VIP) and the structurally related peptide histidine isoleucine (PHI) in segments of bovine and human intrapulmonary artery. In both species, VIP caused nearly complete relaxation of precontracted vessel segments. The EC50 was 1.3 ± 0.3 × 10–9 M (mean ± SD) in bovine and 3.4 ± 0.4 × 10–9 M in human pulmonary artery. The response to VIP was not endothelium-dependent and it was not affected by either adrenergic and cholinergic blockade or by cyclooxygenase inhibition. PHI also relaxed human and bovine vessels but this related peptide was significantly less effective than VIP. We conclude that VIP is a potent inhibitor of bovine and human pulmonary artery, which appears to act directly on vascular smooth muscle. These data support the concept that VIP may be a neurotransmitter which modulates pulmonary artery tone in both man and cow.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Greenberg, B., Rhoden, K., & Barnes, P. J. (2008). Relaxant Effects of Vasoactive Intestinal Peptide and Peptide Histidine Isoleucine in Human and Bovine Pulmonary Arteries. Blood Vessels. https://doi.org/10.1159/000158670
Vancouver
Greenberg B, Rhoden K, Barnes PJ. Relaxant Effects of Vasoactive Intestinal Peptide and Peptide Histidine Isoleucine in Human and Bovine Pulmonary Arteries. Blood Vessels. 2008. doi:10.1159/000158670
BibTeX
@article{Greenberg2008,
author = {Greenberg, B and Rhoden, K and Barnes, P J},
title = {Relaxant Effects of Vasoactive Intestinal Peptide and Peptide Histidine Isoleucine in Human and Bovine Pulmonary Arteries},
journal = {Blood Vessels},
year = {2008},
doi = {10.1159/000158670}
}
EUVIMED